PATENT CLAIM ANALYSIS

Application Number: 15938762
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["424", "093710"]

Abstract:
Provided herein are methods of treating an IDH mutant cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an all-trans retinoic acid (ATRA). In some embodiments, the methods increase an NK-cell-mediated immune response and/or a T cell-mediated immune response to the cancer. In some embodiments, the cancer is a glioma or a chondrosarcoma. In some embodiments, the expression of one or more NKG2D ligands (e.g., ULBP1 and ULBP3) is increased in a tumor microenvironment of the cancer. In some embodiments, CCL2 production, the number of NK cells, and/or apoptosis of tumor cells is increased in a tumor microenvironment of the cancer. In some embodiments, the subject has an IDH1 mutation at arginine 132 or an IDH2 mutation at arginine 172. In some embodiments, method reduces growth of a tumor.

Claim (Index 6):
The method of  claim 1 , wherein expression of one or more NKG2D ligands is increased in a tumor microenvironment of the cancer.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 90.0
- Lexical Diversity: 2.18056
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15505777', '13060191', '15238161', '15589615', '14102730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6961663260797353
- 35 USC 102 Novelty (BERT): 0.5197331939034584
- Combined Prediction Score: 0.6785230128621077
- Mean Citation Score: 257.90158600000007
- Max Citation Score: 269.47675
- Similarity Product: 174.81143061625957

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test